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OBJECTIVES We sought to determine the prevalence of treatable left ventricular (LV) systolic dysfunction
(LVSD) in patients who present with their first noncardiac vascular episode.
BACKGROUND Screening for LV dysfunction in patients who present with their first stroke (cerebrovascular
accident), their first transient ischemic attack (TIA) or their first manifestation of peripheral
vascular disease (PVD) may represent a golden opportunity to identify treatable LV
dysfunction, and so their known high incidence of sudden cardiac death may be reduced.
METHODS Participating in this study were 522 (75%) of 700 consecutive patients (302 patients with
stroke, TIA or PVD and 220 age- and gender-matched control subjects). Each underwent a
full clinical assessment, 12-lead electrocardiography and two-dimensional echocardiography.
Left ventricular dysfunction was defined as LV ejection fraction 40%.
RESULTS Seventy-two (28%) patients with vascular disease and 11 (5.5%) control subjects were found
to have LVSD. Twenty-six (28%) stroke patients, 22 (26%) patients with TIA and 24 (31%)
patients with PVD had LVSD. Left ventricular systolic dysfunction was symptomatic in 44%
of patients and in 35% of control subjects.
CONCLUSIONS Left ventricular systolic dysfunction is five times more common among patients with stroke,
TIA and PVD than among age- and gender-matched control subjects. Asymptomatic LVSD
is more common than symptomatic LVSD in these patients. These findings suggest that
routine screening of all patients with noncardiac vascular episodes for LVSD should now be
considered. Future studies should investigate whether identifying and treating LVSD in these
patients would reduce their known high rate of cardiac death. (J Am Coll Cardiol 2002;39:
219–24) © 2002 by the American College of Cardiology
Symptomatic heart failure is present in 0.4% to 2% of the
population and continues to rise as the population ages (1).
In order to substantially reduce and/or delay the incidence
of heart failure and its consequences, we need to detect and
treat presymptomatic left ventricular (LV) dysfunction.
In the Western world, heart failure is largely due to LV
systolic dysfunction (LVSD). It is clear that angiotensin-
converting enzyme (ACE) inhibitors and beta-blockers can
prevent the progression of LVSD to heart failure and reduce
morbidity and mortality (2–4). In addition, spironolactone,
warfarin and implantable cardioverter-defibrillators (ICDs)
are possible therapies in selected cases. Indeed, ICD place-
ment is a new therapy that particularly benefits those with
LVSD (5,6).
Left ventricular systolic dysfunction is found in 2% to
12% of the general population, with60% of patients being
asymptomatic (7). Previous screening studies have focused
on the general population, but screening whole populations
is unlikely to be cost-effective. More selective screening for
LVSD is already routinely undertaken in post-myocardial
infarction (MI) patients while they are in the coronary care
unit. Patients who present with their first noncardiac
vascular episode represent another high-risk group that
might be worth screening for treatable LVSD. Currently,
such patients in Europe will only get a routine echocardio-
gram if they have atrial fibrillation. Echocardiography re-
sources are inadequate to image all such patients routinely,
certainly in nonteaching hospitals. Previous surgical and
angiographic studies of patients with noncardiac vascular
episodes have found LVSD in 16% to 68% of patients with
vascular disease who are awaiting carotid endarterectomy or
femoral revascularization (8,9). All of these previous results
have come from small surgical series of patients with
vascular disease; therefore, they are heavily biased, because
LVSD is likely to be a major factor causing vascular patients
to be excluded from surgical series.
Thus, the first reason for wanting to know the extent of
LVSD among patients with noncardiac vascular episodes is
that such patients might have a great amount of LVSD, and
it may be very cost-effective to screen for treatable LVSD in
such patients. The second reason is that patients who have
had noncardiac vascular episodes are known to be at
exceptionally high risk of cardiac death, and because of that,
we commonly optimize the treatment of conventional risk
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factors, such as blood pressure and cholesterol, in such
patients. However, in clinical practice, we do not routinely
seek a much bigger risk factor (i.e., LVSD) in these patients,
despite the fact that specific treatments exist for LVSD that
are known to reduce cardiac deaths (for example, a patient
with a transient ischemic attack [TIA] could well have an
arrhythmic death due to asymptomatic LVSD, despite
optimal control of blood pressure and cholesterol). Better
knowledge about the incidence of LVSD in such patients
would provide information on these two issues. First, are
such patients an enriched source of LVSD? This might raise
the possibility of screening such patients for LVSD. Second,
do these patients have enough LVSD to be an independent
contributor to the high rate of cardiac death that they are
known to experience? If so, screening for and vigorously
treating asymptomatic LVSD in such patients may be a
cost-effective way of reducing their currently high rate of
cardiac death.
We report an epidemiologic survey, using two-
dimensional echocardiography, to establish the prevalence
and clinical characteristics of LVSD in patients presenting
to the hospital with their first noncardiac vascular episode
(i.e., stroke, TIA or overt peripheral vascular disease
[PVD]), and we compare these patients with age- and
gender-matched control subjects recruited from general
practice.
METHODS
A total of 700 men and women, aged 45 to 87 years, were
invited to participate. We identified 400 patients with
stroke, TIA or PVD at first presentation to Ninewells
Hospital (Dundee, Scotland, United Kingdom), and we
matched them with 300 age- and gender-matched control
subjects recruited from the general practice population. Of
the 700 subjects who were initially approached, 522 subjects
agreed to participate (75% response rate). Those patients
who declined to participate were generally older and male
and had prolonged hospital stays for their vascular episode.
Stroke patients were identified from the hospital’s stroke
admission database, and this diagnosis was confirmed on
computed tomographic scan. Patients with TIA included
only those patients with classic symptoms. These patients
were recruited from referrals to the vascular laboratory for
ultrasound of the carotid artery. Their clinical history, not
their ultrasound findings, determined inclusion in the study
cohort. Patients with vague symptoms or a referral for
investigation of dizzy spells/funny turns were excluded.
Patients with PVD were also recruited from the vascular
laboratory, based on a history of new-onset, intermittent
claudication in conjunction with an ankle-arm index 0.8
at rest. Patients with PVD with acute leg ischemia were
excluded. Any vascular patient with a previous stroke, TIA
or PVD was excluded, as this would constitute their second
noncardiac vascular event. A previous MI or history of
coronary artery disease did not preclude any patient from
being recruited. Age- and gender-matched control subjects
were recruited from the general practice population. These
subjects differed from patients solely by the absence of a
previous stroke or TIA or history of PVD. Control subjects
were matched for age and gender according to our own
hospitals’ MEMO database, which represents the general
population (10). Patients with a cerebrovascular accident,
TIA or PVD were removed from the control group.
Two-dimensional echocardiography (Sonos 2000,
Hewlett-Packard, Palo Alto, California) was performed
with each patient reclining at 40° in the left lateral position.
Images were acquired and stored on videotape and analyzed
on-line. The LV ejection fraction (LVEF) was measured by
using the biplane summation method of discs (modified
Simpson’s rule) (11). Each ejection fraction was taken as a
mean value of three cardiac cycles. Echocardiograms were
deemed acceptable if 75% of the endocardium was visible.
Echocardiography was performed by a single observer
(R. K.). A random sample of 50 echocardiograms was
repeated, with the first results concealed by the same
observer, and 25 of these were re-analyzed by a second
observer. The interobserver variability was 8%, and the
intraobserver variability was 8.9%.
Each patient underwent a full history and physical exam-
ination. Symptoms of breathlessness were recorded in ac-
cordance with New York Heart Association functional class.
Each patient in this study gave written, informed consent.
The local Tayside Ethics Committee approved the study.
Blood pressure was recorded with an automated sphyg-
momanometer. Each reading was taken as an average of
three readings from both arms, with the patient seated after
a 5-min rest.
Standard 12-lead electrocardiograms (ECGs) were re-
corded and classified for the presence of atrial fibrillation,
atrial flutter, left bundle branch block, LV hypertrophy,
pathologic Q waves and ischemia. Ischemia included ST-
segment depression, any T-wave inversion and Q waves
(12).
The clinical definitions that we used in this study are as
follows. Ischemic heart disease (IHD) was defined as a history
of angina, MI or taking anti-anginal medications. Hyper-
tension included a known history of such or a history of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
ECG  electrocardiogram
HOPE Heart Outcomes Prevention Evaluation study
ICD  implantable cardioverter-defibrillator
IHD  ischemic heart disease
LV  left ventricular
LVEF  left ventricular ejection fraction
LVSD  left ventricular systolic dysfunction
MI  myocardial infarction
PVD  peripheral vascular disease
TIA  transient ischemic attack
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taking antihypertensive medications, or both, or blood
pressure 160/95 mm Hg at presentation. Hypercholester-
olemia referred to a patient with known total serum choles-
terol 5.2 mmol/l or a patient on a cholesterol-lowering
diet, medication or both. Smoking referred to patients with
a history of cigarette smoking at the time of the noncardiac
event or to current smokers. It did not include patients who
had stopped smoking before their initial presentation to
hospital. Alcohol excess included patients who admitted to
alcohol consumption above the recommended weekly allow-
ances. Left ventricular systolic dysfunction was defined as an
ejection fraction 40%. Symptomatic LV dysfunction was
defined by the presence of symptoms of cardiac dyspnea,
ankle swelling, fatigue, orthopnea and paroxysmal nocturnal
dyspnea. Asymptomatic LV dysfunction was defined by the
absence of symptoms of cardiac dyspnea.
Statistical analysis. The data were analyzed using the
STATA (X) statistics program (version 5, 1997, Timberlake
Consultants Ltd., London, UK). The results were prepared
separately for patients with vascular disease and control
subjects. The results presented are univariate odds ratios.
Proportions were compared between groups by using the
chi-square test. Multivariate analysis was done using logistic
regression after adjusting for age and gender. Model testing
was done using graphs of residuals, leverages and areas
under the receiver-operating characteristic curves.
RESULTS
We were able to measure the ejection fraction in 255
patients with stroke, TIA or PVD and in 202 control
subjects. There were 245 (54%) men and 212 (46%) women.
The epidemiologic characteristics of the patients with
stroke, TIA and PVD and control subjects are shown in
Table 1. Of patients with stroke, TIA or PVD, 27% had
IHD, 48% had hypertension and 12% with diabetes, as
compared with 16% of control subjects with IHD, 35% with
hypertension and 5% with diabetes.
The mean LVEF in patients with stroke, TIA or PVD
was 45  8.9% (range 17% to 68%, 95% confidence interval
[CI] 44% to 46%). In control subjects, the mean LVEF in
all patients was 50.6  6.9% (range 20% to 63%, 95% CI
49.7% to 51.6%). In those patients with LVSD, the mean
LVEF was 34.5  5.2% (range 16% to 40%, 95% CI 33.3%
to 35.7%) in the stroke, TIA and PVD group, as compared
with 33  6.5% (range 20% to 40%, 95% CI 29.3% to
36.7%) in the control group.
Left ventricular systolic dysfunction was found in 72
patients with stroke, TIA and PVD (28%), as compared
with 11 age- and gender-matched control subjects (5.5%).
Twenty-six (28%) stroke patients, 22 (26%) patients with
TIA and 24 (31%) patients with PVD had LVSD. In the
stroke, TIA and PVD group, LVSD was more common in
men than in women (20% vs. 9%), and in the control group,
4.6% of men versus 1% of women had LVSD. As age
increased up to 75 years, so did the prevalence of LVSD
(Figs. 1 and 2).
Symptomatic LVSD was found in 44% of the stroke,
TIA and PVD group and in 35% of the control group.
Asymptomatic LVSD was found in 56% of the stroke, TIA
and PVD group and in 65% of the control group.
Table 2 outlines the risk factors for LVSD in both patient
groups. Of the patients with stroke, TIA or PVD with
LVSD, 54% had no history of IHD, whereas 91% of control
subjects with LVSD had a history of IHD. The presence of
diabetes mellitus and IHD, together with noncardiac vas-
cular episodes, significantly increased the likelihood of
LVSD. In the control group, IHD, diabetes and atrial
fibrillation significantly increased the likelihood of LVSD.
Table 1. Characteristics of Patients and Control Subjects
Patients
(%)
Control Subjects
(%)
Mean age in years (range) 68  6 (45–87) 68  6.7 (45–87)
Gender
Male 146 (57%) 99 (49%)
Female 109 (43%) 103 (51%)
History
IHD 69 (27%) 32 (16%)
BP 122 (48%) 70 (35%)
DM 32 (12%) 10 (5%)
Cholesterol 108 (42%) 28 (14%)
Smoker 198 (78%) 138 (69%)
Excessive alcohol consumption 16 (6%) 24 (12%)
Atrial fibrillation 28 (11%) 7 (3.5%)
Stroke 92 (36%) —
TIA 85 (33%) —
PVD 78 (31%) —
Heart failure symptoms 82 (32%) 33 (16%)
Medications
ACE inhibitor 48 (19%) 24 (12%)
Diuretic 62 (24%) 36 (18%)
Beta-blocker 50 (20%) 30 (15%)
Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; BP  blood pressure; DM  diabetes
mellitus; IHD  ischemic heart disease; PVD  peripheral vascular disease; TIA 
transient ischemic attack.
Figure 1. Number of men with left ventricular ejection fraction 40%.
Solid bars  patients with stroke, transient ischemic attack or peripheral
vascular disease; open bars  control subjects.
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Atrial fibrillation alone did not predict LVSD in patients
with stroke, TIA or PVD. Sixty-two patients with stroke,
TIA or PVD (86%) and 9 control subjects (82%) with
LVSD were in sinus rhythm (Table 2).
In both groups of patients, an abnormal ECG was much
more likely to be associated with LVSD than with normal
LV function. Of all patients with stroke, TIA or PVD, 60%
had abnormal ECGs, as compared with 29% of control
subjects. In the patients with stroke, TIA or PVD with
ECG evidence of IHD, 64% had LVSD, as compared with
36% with normal LV function (p  0.001). In control
subjects with an ischemic ECG, 82% had LVSD and 19%
had normal LV function (Table 3).
In a more detailed logistic regression analysis, the inde-
pendent, useful predictors of LVSD were IHD and an
abnormal ECG, particularly an ischemic ECG, in the
presence of a noncardiac vascular event (Table 4). In
patients with more severe LVSD (ejection fraction 35%),
a history of IHD and an abnormal ECG remained signif-
icant risk factors for development of LVSD in both patients
and control subjects, as the severity of LV dysfunction
progressed.
Hypercholesterolemia was observed in more patients with
stroke, TIA or PVD than in control subjects, but it did not
predict LVSD. Excessive alcohol consumption was more
common among patients with normal LV function than
among those with LVSD (7% vs. 4%). Alcohol excess was
less frequent among patients with stroke, TIA or PVD than
among control subjects (6% vs. 12%).
Of the patients with stroke, TIA or PVD, 60% were
taking aspirin. Only 24% of control subjects with LVSD
were taking an ACE inhibitor, a diuretic, a beta-blocker or
combination of these medications. Of the control subjects
with LVSD, 52% were taking a diuretic, an ACE inhibitor,
a beta-blocker or a combination of these.
DISCUSSION
Left ventricular systolic dysfunction is extremely common in
patients who present to the hospital with their first stroke or
TIA or their first presentation of PVD. We have found that
28% of these patients have LVSD, as compared with 5.5%
of age- and gender-matched control subjects. This amounts
to five times more LVSD in patients with noncardiac
vascular disease than in the general population. As with
studies in Glasgow and Southampton, asymptomatic LVSD
was found in almost two-thirds of all patients with LVSD
(7,13). As for patients with stroke, TIA or PVD, there are
no previous studies available to make a direct comparison
with our study. It should be remembered that many patients
with stroke or PVD will often be unable to exercise to
become symptomatic, and this may increase the prevalence
of “hidden” asymptomatic LVSD in these patients.
If we classify LVSD by its severity, the prevalence of mild
LVSD was much greater than that of severe LVSD in both
study groups. In comparison to the population studies of
McDonagh et al. (7) and Morgan et al. (13), we have
certainly identified much more LVSD in our high-risk
patients than they found in their population screening.
Prevalence of LVSD as defined by echocardiography.
We chose to define LVSD as LVEF 40%. We prespeci-
fied this value as our cutoff, because it represents the value
used in many ACE inhibitor studies of patients with LV
dysfunction, and this is the level of function below which
ACE inhibitor therapy is commonly prescribed. Unfortu-
nately, most studies of LVSD using echocardiography have
selected different cutoff values to represent LVSD (7,13).
We chose 40% as a compromise between some studies that
used LVEF 30% to 35% and some that used LVEF
45%. The prevalence of LVSD would be higher (48%) if
the cutoff value were increased to LVEF 45%, as in the
Southampton study (13). It will be interesting to learn the
follow-up analysis of this intermediate group (LVEF 40%
to 45%) of patients to see whether they also progress to
heart failure, and its resultant mortality and morbidity.
Previous studies have shown that echocardiographic mea-
Table 2. Relationship Between Risk Factors and the Presence of
LVSD In Patients With Stroke, TIA or PVD as Compared
With Age- and Gender-Matched Control Subjects
Risk Factor
Patients
(n  255)
Control Subjects
(n  202)
LVSD
(n  72)
(28%)
Normal
LV Function
(n  183)
(72%)
LVSD
(n  11)
(5.5%)
Normal
LV Function
(n  191)
(94.5%)
Hypertension 33 (46%) 89 (48%) 4 (27%) 66 (36%)
Diabetes mellitus 15 (21%) 17 (8.7%) 3 (27%) 7 (4%)
IHD/MI 33 (46%) 36 (20%) 10 (91%) 22 (12%)
IHD/HTN 53 (74%) 105 (57%) 11 (100%) 76 (41%)
AF 10 (14%) 18 (10%) 2 (18%) 5 (3%)
Abnormal ECG 59 (82%) 95 (50%) 10 (91%) 48 (26%)
Ischemic ECG 46 (64%) 67 (37%) 9 (82%) 37 (19%)
Data are presented as the number (%) of patients or control subjects.
AF  atrial fibrillation; ECG  electrocardiogram; HTN  hypertension;
IHD  ischemic heart disease; LV  left ventricular; LVSD  left ventricular
systolic dysfunction; MI  myocardial infarction.
Figure 2. Number of women with left ventricular ejection fraction 40%.
Solid bars  patients with stroke, transient ischemic attack or peripheral
vascular disease; open bars  control subjects.
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surements of LV function correlate extremely well with both
radionuclide and contrast ventriculographic measurements
(14). Interestingly, the prevalence of LVSD in our patients
with stroke, TIA or PVD was even greater than that
detected by open-access echocardiography clinics in the
United Kingdom, where patients suspected of having
LVSD are referred by their family doctor. Most open-access
echocardiography clinics report a 20% to 32% prevalence of
LVSD in selected populations (15). In patients taking
diuretics, the prevalence of LVSD is usually around 21%
(16).
Clinical significance of LVSD in noncardiac vascular
disease. A key point concerning patients with noncardiac
vascular episodes is that they are well known to have a high
incidence of subsequent cardiac death (17). The assumption
has generally been made that their cardiac death is due to
fresh ischemia/infarction, but clearly it is also distinctly
possible, in view of these results, that some cardiac deaths
are “arrhythmic,” due to LVSD, in which case, beta-
blockade or even ICD therapy might reduce cardiac deaths
in those patients with asymptomatic LVSD. In addition,
ACE inhibitors might slow down and/or prevent the
development of overt heart failure and hospital admissions.
Furthermore, the judicious use of warfarin in patients with
LVSD with previous vascular episodes might prevent fur-
ther embolic events, even in those in sinus rhythm, as it
appeared to do in the Survival And Ventricular Enlarge-
ment (SAVE) trial (2). Indeed, it is ironic that after a
noncardiac vascular episode, it is standard practice to opti-
mize the treatment of distant risk factors, such as blood
pressure and cholesterol, and yet we ignore whether a bigger
risk factor, like LVSD, already exists. This is even stranger
when one considers that LVSD is easily detected by a
noninvasive test and easily treated by beta-blockers, ACE
inhibitors, spironolactone, warfarin, ICDs or a combination
of these.
The recent Heart Outcomes Prevention Evaluation
(HOPE) study has shown that treating all high-risk patients
with ramipril will reduce cardiac events (18). However, we
must remember that, so far, the HOPE study is the only
study to show such benefits. Indeed, in the QUinapril in
Ischemic Events Trial (QUIET), quinapril did not prevent
MI or reduce ischemic events in patients with coronary
artery disease with normal LV function (19). Most com-
mentators have suggested that we await the results of the
European trial on Reduction of Cardiac Events with Per-
indopril in Stable Coronary Artery Disease (EUROPA) and
the Prevention of Events with Angiotensin-Converting
Enzyme inhibition (PEACE) study before we consider
putting all vascular patients on ACE inhibitors, indepen-
dent of their LV function (20,21). However, even if the
HOPE strategy were implemented in full, this does not
invalidate our suggestion that LVSD should be identified in
these patients, because a diagnosis of LVSD will influence
whether other non-ACE inhibitor therapies are initiated in
these patients (i.e., the possibility of using beta-blockade,
ICDs, spironolactone and warfarin) and increases the im-
portance of differentiating between LVSD and normal LV
systolic function in these patients (4,22–24).
Should we screen for LVSD? The large number of pa-
tients with LVSD that we have identified by echocardiog-
raphy suggests that screening of patients with stroke, TIA
or PVD for LVSD should be considered. If cost constraints
make this difficult, screening could be selective by focusing
on those with abnormal ECGs and/or a history of MI, but
we have shown that echocardiographic screening should to
Table 3. Epidemiology of LVSD (Ejection Fraction 40%)*
Variable
Patients Control Subjects
OR 95% CI p Value OR 95% CI p Value
Female gender 0.49 0.27–0.87 0.015 0.2 0.04–0.95 0.04
IHD/MI† 3.46 1.9–6.23 0.0001 76 9.3–630 0.001
Diabetes 2.58 1.2–5.48 0.015 9.85 2.1–45 0.003
Hypertension 1.08 0.3–3.48 NS 0.89 0.51–1.55 NS
Hypercholesterolemia — — NS — — NS
Cigarette smokers — — NS — — NS
Abnormal ECG 4.2 2.2–8.19 0.0001 30 3.7–240 0.001
Ischemic ECG 3.14 1.7–5.53 0.0001 22.3 4.6–109 0.001
*Logistic regression analysis with unadjusted odds ratio. †Includes angina; 80% of patients had a myocardial infarction.
CI  confidence interval; NS  not statistically significant; OR  odds ratio; other abbreviations as in Table 2.
Table 4. Multiple Logistic Regression Analysis* of Risk Factors for Left Ventricular Systolic
Dysfunction (Ejection Fraction 40%) in Patients and Control Subjects
Variable
Patients Control Subjects
OR 95% CI p Value OR 95% CI p Value
IHD/MI 2.37 1.26–4.45 0.007 46 4.5–451 0.001
Abnormal ECG 3.56 1.77–7.2 0.0001 8.6 0.92–80 0.06
Diabetes mellitus 2.46 1.07–5.61 0.033 10.8 0.56–203 0.115
*Adjusted for age and gender.
Abbreviations as in Tables 2 and 3.
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be done in more patients than just those with atrial
fibrillation, which is the current practice. A significant
amount of cardiac deaths might be preventable by identify-
ing and aggressively treating LVSD in patients who present
with their first noncardiac vascular episode.
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